Status:
COMPLETED
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
Lead Sponsor:
GE Healthcare
Conditions:
Lewy Body Dementia
Non-DLB Dementia
Eligibility:
All Genders
55-90 years
Phase:
PHASE3
Brief Summary
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects det...
Detailed Description
GEHC had decided notto provide this detail
Eligibility Criteria
Inclusion
- Subjects must be adults between 55 to 90 years of age with an established diagnosis for dementia in accordance with DSM-IV criteria and have to fulfil at least one of the following: The ICC criteria for probable and possible DLB, the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) for Alzheimer's Disease (AD), or the National Institute of Neurological and Communicative Disorders and Association Internationale Pour la Recherche et l'Enseignement en Neurosciences (NINCS-AIREN) for Vascular Dementia (VaD).
Exclusion
- Subjects are not eligible if they have a Mini Mental State Examination (MMSE) score of \<10 and use medication known or suspected to interact with the striatal uptake DaTSCAN to the dopamine transporter.
- Furthermore subjects are not eligible if they were diagnosed with idiopathic Parkinson's Disease (PD), with persistent severe depression, normal pressure hydrocephalus, multiple system atrophy, cortico-basal degeneration or Huntington's Chorea Disease.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT00209456
Start Date
November 1 2003
Last Update
May 16 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amersham Buchler GmbH Co. KG
Ismaning, Germany